Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceuticalcompany focusing on RNA-modulating therapeutics for rare diseaseswith high unmet need, announced that during an extraordinarygeneral meeting of shareholders held today, Prosensa obtainedshareholder approval for certain matters relating to the previouslydisclosed tender offer by BioMarin to purchase all of theoutstanding shares of Prosensa. This approval includes approval of certain transactions that areintended to be consummated after the completion of the tenderoffer. Obtaining shareholders' approval of the itemssubmitted to a vote at the meeting satisfies a condition to theclosing of the tender offer. The approvals will becomeeffective upon the closing. On December 12, 2014, BioMarin Falcons B.V. and BioMarin GiantsB.V., each a wholly owned direct or indirect subsidiary of BioMarinPharmaceutical Inc., commenced the tender offer to acquire all ofthe outstanding ordinary shares of Prosensa for $17.75 per shareupfront plus a right to receive up to an additional $4.14 per sharebased on regulatory approval of drisapersen in the United Statesand Europe, in each case, without interest and less any applicablewithholding taxes. The tender offer is set to expire at6:00 p.m., New York City time, on January 14, 2015, unless extendedor earlier terminated. The tender offer remains subject tocertain conditions described in the tender offer statement onSchedule TO filed by BioMarin Falcons B.V. and BioMarin Giants B.V.with the United States Securities and Exchange Commission (the"SEC") on December 12, 2014 and amended on December 24, 2014,December 31, 2014 and January 6, 2015, including the condition thatat least 80% of Prosensa's outstanding shares be validly tenderedand not withdrawn prior to the expiration of the offer. Notes to editors About Prosensa Holding N.V. Prosensa is a biotechnology company engaged in thediscovery and development of RNA-modulating therapeutics for thetreatment of genetic disorders. Its primary focus is on rareneuromuscular and neurodegenerative disorders with a large unmetmedical need, including Duchenne muscular dystrophy (DMD), MyotonicDystrophy and Huntington's disease.
Prosensa's current portfolio includes six compounds for thetreatment of DMD, all of which have received orphan drug status inthe United States and the European Union. The compounds use aninnovative technique called exon-skipping to provide a personalizedmedicine approach to treat different populations of DMD patients. www.prosensa.comAbout DMD Duchenne muscular dystrophy is the most common fatal geneticdisorder diagnosed in childhood, affecting approximately up to 1 in3,500 live male births. DMD is caused by mutations in the gene thatencodes for dystrophin, a protein that is important for musclefunction. Patients suffer from progressive loss of muscle function,often making them wheelchair bound before the age of 12.Respiratory and cardiac muscle can also be affected by the disease.Few patients survive the age of 30. There is currently no cure forDMD. Forward Looking Statements SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT AREFORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING THEEXPECTED CONSUMMATION OF THE ACQUISITION, WHICH INVOLVES A NUMBEROF RISKS AND UNCERTAINTIES, INCLUDING THE SATISFACTION OF CLOSINGCONDITIONS FOR THE ACQUISITION, SUCH AS REGULATORY APPROVAL FOR THETRANSACTION AND THE TENDER OF AT LEAST 80% OF THE OUTSTANDINGORDINARY SHARES OF PROSENSA, THE POSSIBILITY THAT THE TRANSACTIONWILL NOT BE COMPLETED AND OTHER RISKS AND UNCERTAINTIES DISCUSSEDIN PROSENSA'S PUBLIC FILINGS WITH THE SEC, INCLUDING THE "RISKFACTORS" SECTIONS OF PROSENSA'S ANNUAL REPORT ON FORM 20-F FOR THEYEAR ENDED DECEMBER 31, 2013, AS WELL AS THE TENDER OFFER DOCUMENTSFILED BY BIOMARIN AND THE SOLICITATION/RECOMMENDATION STATEMENTFILED BY PROSENSA. THESE STATEMENTS ARE BASED ON CURRENTEXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS, AND INVOLVEKNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAYCAUSE RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS TOBE MATERIALLY DIFFERENT FROM ANY FUTURE STATEMENTS. THESESTATEMENTS ARE GENERALLY IDENTIFIED BY WORDS OR PHRASES SUCH AS"BELIEVE", "ANTICIPATE", "EXPECT", "INTEND", "PLAN", "WILL", "MAY","SHOULD", "ESTIMATE", "PREDICT", "POTENTIAL", "CONTINUE" OR THENEGATIVE OF SUCH TERMS OR OTHER SIMILAR EXPRESSIONS. IFUNDERLYING ASSUMPTIONS PROVE INACCURATE OR UNKNOWN RISKS ORUNCERTAINTIES MATERIALIZE, ACTUAL RESULTS AND THE TIMING OF EVENTSMAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING DISCUSSED INTHE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUERELIANCE ON THESE STATEMENTS. BIOMARIN AND PROSENSA DISCLAIMANY INTENT OR OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTSAS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE PERIOD COVERED BYTHIS REPORT OR OTHERWISE.
Additional Information and Where to Find itTHIS COMMUNICATION IS FOR INFORMATIONAL PURPOSES ONLY AND DOESNOT CONSTITUTE EITHER AN OFFER TO PURCHASE OR A SOLICITATION OF ANOFFER TO SELL ANY ORDINARY SHARES OF PROSENSA OR ANY OTHERSECURITIES. BIOMARIN HAS FILED A TENDER OFFER STATEMENT ON SCHEDULE TO,INCLUDING AN OFFER TO PURCHASE, A LETTER OF TRANSMITTAL AND RELATEDMATERIALS, WITH THE SEC, AND PROSENSA HAS FILED ASOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WITH THESEC. THE OFFER TO PURCHASE PROSENSA SHARES IS ONLY BEING MADEPURSUANT TO THE OFFER TO PURCHASE, THE LETTER OF TRANSMITTAL ANDRELATED MATERIALS FILED WITH THE SEC BY BIOMARIN AS A PART OF ITSSCHEDULE TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTHTHE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATIONSTATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TOTIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE OFFER,INCLUDING ITS TERMS AND CONDITIONS, AND SHOULD BE READ CAREFULLYBEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER. INVESTORSAND SECURITY HOLDERS MAY OBTAIN FREE COPIES OF THESE STATEMENTS ANDOTHER MATERIALS FILED WITH THE SEC AT THE WEBSITE MAINTAINED BY THESEC AT WWW.SEC.GOV, OR BY DIRECTING REQUESTS FOR THESOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 TOPROSENSA'S INVESTOR RELATIONS DEPARTMENT, J.H. OORTWEG 21, 2333 CHLEIDEN, THE NETHERLANDS, TELEPHONE NUMBER +31 (0)71 33 22 100, ORFROM PROSENSA'S WEBSITE, IR.PROSENSA.EU, OR, FOR THE OFFER TOPURCHASE ON SCHEDULE TO AND THE OTHER RELATED MATERIALS (A PORTIONOF WHICH ARE ATTACHED HERETO AS APPENDIX C), TO THE INFORMATIONAGENT FOR THE TENDER OFFER, MORROW & CO., TOLL-FREE AT(800)-267-0201 OR VIA EMAIL AT PROSENSA.INFO@MORROWCO.COM.
CONTACT: Prosensa Holding N.V. Celia Economides, Senior Director IR & Corporate Communications Phone: +1 917 941 9059 Email: firstname.lastname@example.org